{"id":"belimumab-plus-early-vaccination","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Bronchitis"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Belimumab is a monoclonal antibody that binds to and neutralizes soluble B-lymphocyte stimulator (BLyS), a key cytokine that promotes B cell survival and differentiation. By reducing BLyS signaling, belimumab decreases pathogenic autoantibody-producing B cells. The combination with early vaccination aims to leverage the immunosuppressive window created by belimumab to promote tolerogenic responses and prevent disease flares.","oneSentence":"Belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cells, combined with early vaccination to enhance immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:28:16.939Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE) with early vaccination strategy"}]},"trialDetails":[{"nctId":"NCT01597492","phase":"PHASE4","title":"A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2012-05-31","conditions":"Systemic Lupus Erythematosus","enrollment":79}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BENLYSTA™"],"phase":"marketed","status":"active","brandName":"Belimumab plus Early Vaccination","genericName":"Belimumab plus Early Vaccination","companyName":"Human Genome Sciences Inc., a GSK Company","companyId":"human-genome-sciences-inc-a-gsk-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"Belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cells, combined with early vaccination to enhance immune response. Used for Systemic lupus erythematosus (SLE) with early vaccination strategy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}